Heron Therapeutics (HRTX)
(Real Time Quote from BATS)
$1.98 USD
0.00 (0.00%)
Updated Sep 24, 2024 02:11 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Balance Sheet
Fiscal Year End for Heron Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 80 | 85 | 158 | 208 | 391 |
Receivables | 60 | 52 | 36 | 42 | 40 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 42 | 55 | 48 | 42 | 25 |
Other Current Assets | 6 | 14 | 13 | 22 | 23 |
Total Current Assets | 189 | 205 | 254 | 314 | 479 |
Net Property & Equipment | 20 | 22 | 24 | 23 | 20 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 16 | 18 | 0 | 0 |
Total Assets | 223 | 251 | 306 | 354 | 513 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 7 | 6 |
Accounts Payable | 3 | 3 | 4 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 73 | 76 | 65 | 92 | 86 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 80 | 82 | 71 | 103 | 97 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 149 | 149 | 149 | 0 | 0 |
Long-Term Debt | 24 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 256 | 237 | 228 | 117 | 109 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,871 | 1,808 | 1,690 | 1,628 | 1,568 |
Retained Earnings | -1,906 | -1,795 | -1,613 | -1,393 | -1,165 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -34 | 14 | 78 | 236 | 404 |
Total Liabilities & Shareholder's Equity | 223 | 251 | 306 | 354 | 513 |
Total Common Equity | -34 | 14 | 78 | 236 | 404 |
Shares Outstanding | 150.00 | 118.80 | 101.90 | 90.80 | 90.00 |
Book Value Per Share | -0.23 | 0.11 | 0.76 | 2.60 | 4.49 |
Fiscal Year End for Heron Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 67 | 72 | 80 | 77 | 33 |
Receivables | 74 | 65 | 60 | 64 | 77 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 43 | 42 | 42 | 42 | 45 |
Other Current Assets | 7 | 7 | 6 | 11 | 11 |
Total Current Assets | 191 | 186 | 189 | 194 | 165 |
Net Property & Equipment | 16 | 19 | 20 | 21 | 21 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 8 | 8 | 8 | 9 |
Total Assets | 218 | 218 | 223 | 229 | 201 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 1 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 67 | 71 | 73 | 75 | 82 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 80 | 75 | 80 | 80 | 87 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 150 | 150 | 149 | 149 | 149 |
Long-Term Debt | 25 | 24 | 24 | 24 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 256 | 252 | 256 | 257 | 241 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 1 | 1 |
Capital Surplus | 1,879 | 1,874 | 1,871 | 1,866 | 1,830 |
Retained Earnings | -1,918 | -1,909 | -1,906 | -1,895 | -1,870 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -38 | -34 | -34 | -28 | -39 |
Total Liabilities & Shareholder's Equity | 218 | 218 | 223 | 229 | 201 |
Total Common Equity | -38 | -34 | -34 | -28 | -39 |
Shares Outstanding | 150.60 | 150.60 | 150.00 | 140.70 | 140.70 |
Book Value Per Share | -0.25 | -0.22 | -0.23 | -0.20 | -0.28 |